FDA Approves Enhertu® for HER2-Low MBC - Metastatic Breast Cancer Trial Talk

Special Topics

On August 5, 2022, the FDA approved trastuzumab deruxtecan (Enhertu®) for the treatment of people with HER2-low MBC who have received chemotherapy. This new approval is based on results from the DESTINY-Breast04 phase III trial. The drug was previously approved only for people with HER2-positive MBC.

Last Modified on September 26, 2023

Tags:

SEARCH OUR SITE

for past articles or specific information.